Omar Taco
Overview
Explore the profile of Omar Taco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanchez-Baya M, Bolufer M, Vazquez F, Alonso N, Masso E, Paul J, et al.
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004579
Diabetes mellitus (DM) in kidney transplant recipients (KTR) is a risk factor for mortality, increases the risk of infections and, in the long term, can lead to graft loss due...
2.
Bolufer M, Soler J, Molina M, Taco O, Vila A, Macia M
Transpl Int
. 2024 Dec;
37:13204.
PMID: 39654653
Cancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has...
3.
Clos-Sansalvador M, Taco O, Rodriguez-Martinez P, Garcia S, Font-Moron M, Bover J, et al.
J Transl Med
. 2024 Nov;
22(1):1030.
PMID: 39548536
Background: Interstitial fibrosis and tubular atrophy (IFTA) is a critical factor in the prognosis of kidney health. Currently, IFTA quantitation in kidney biopsy samples is crucial for diagnosis and assessing...
4.
Josep R, Carles C, Maria M, Marina U, Javier P, Fredzzia G, et al.
Nefrologia (Engl Ed)
. 2024 Jan;
43 Suppl 2:135-137.
PMID: 38278715
No abstract available.
5.
Cacho J, Burgos E, Molina M, Villegas A, Perez M, Canas L, et al.
Nefrologia (Engl Ed)
. 2022 Oct;
42(3):311-317.
PMID: 36210620
Background: Remdesivir is the only antiviral treatment that has been shown to be useful against SARS-CoV-2 infection. It shorts hospitalization time compared to placebo. Its effects in Kidney transplant (KT)...
6.
Molina M, Burgos E, Cacho J, Juega J, Canas L, Taco O, et al.
Transplant Proc
. 2021 Sep;
53(8):2476-2480.
PMID: 34481646
Background: The treatment of coronavirus disease 2019 (COVID-19) is based on the patient's clinical status and levels of inflammatory biomarkers. The comparative activity of these biomarkers in kidney transplant (KT)...
7.
Cacho J, Burgos E, Molina M, Villegas A, Perez M, Canas L, et al.
Nefrologia
. 2021 Jul;
42(3):311-317.
PMID: 34305226
Background: Remdesivir is the only antiviral treatment that has been shown to be useful against SARS-CoV-2 infection. It shorts hospitalization time compared to placebo. Its effects in kidney transplant (KT)...
8.
Carreras-Planella L, Cucchiari D, Canas L, Juega J, Franquesa M, Bonet J, et al.
J Nephrol
. 2020 Dec;
34(3):861-874.
PMID: 33275196
Background: In kidney transplantation, fibrosis represents the final and irreversible consequence of the pathogenic mechanisms that lead to graft failure, and in the late stages it irremediably precedes the loss...
9.
Carreras-Planella L, Juega J, Taco O, Canas L, Franquesa M, Lauzurica R, et al.
Int J Mol Sci
. 2020 Oct;
21(20).
PMID: 33066346
Use of immunosuppressive drugs is still unavoidable in kidney-transplanted patients. Since their discovery, calcineurin inhibitors (CNI) have been considered the first-line immunosuppressive agents, in spite of their known nephrotoxicity. Chronic...
10.
Jarque M, Crespo E, Melilli E, Gutierrez A, Moreso F, Guirado L, et al.
Clin Infect Dis
. 2020 Feb;
71(9):2375-2385.
PMID: 32076718
Background: Improving cytomegalovirus (CMV) immune-risk stratification in kidney transplantation is highly needed to establish guided preventive strategies. Methods: This prospective, interventional, multicenter clinical trial assessed the value of monitoring pretransplant...